Changes in Beneficial Ownership · 4
Applied Therapeutics Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-02-03
- Issuer
- Applied Therapeutics, Inc.
- Issuer CIK
- 0001697532
- Trading symbol
- APLT
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- Kanter Stacy J.
- Reporting owner CIK
- 0001775404
- Relationship
- Director
- Address
- C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-02-03 | D · Form 4[F1][F2] | 22,500 | D | [F1][F2] | 42,500 | D |
| Common Stock | 2026-02-03 | U · Form 4[F1][F3] | 42,500 | D | [F1][F3] | 0 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
- U · Form 4
- Shares tendered in a change of control
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 1.05 | 2026-02-03 | D · Form 4 | 20,460 | D | [F4] | [F4] | [F4] | Common Stock | 20,460 | 0 | D |
| Stock Option (Right to Buy) | 1.05 | 2026-02-03 | D · Form 4 | 10,230 | D | [F4] | [F4] | [F4] | Common Stock | 10,230 | 0 | D |
| Stock Option (Right to Buy) | 1.05 | 2026-02-03 | D · Form 4 | 16,500 | D | [F4] | [F4] | [F4] | Common Stock | 16,500 | 0 | D |
| Stock Option (Right to Buy) | 1.05 | 2026-02-03 | D · Form 4 | 16,500 | D | [F4] | [F4] | [F4] | Common Stock | 16,500 | 0 | D |
| Stock Option (Right to Buy) | 0.395 | 2026-02-03 | D · Form 4 | 200,000 | D | [F4] | [F4] | [F4] | Common Stock | 200,000 | 0 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
Footnotes
- F1
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").↩ 1↩ 2↩ 3↩ 4
- F2
- Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.↩ 1↩ 2
- F3
- Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.↩ 1↩ 2
- F4
- Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15
Signature 1
- Signed
- /s/ Leslie D. Funtleyder, as attorney-in-fact
- Date
- 2026-02-04
Company context
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG).